Malignant Ascites Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025, the malignant ascites treatment market was valued at USD 619.1 Mn in 2017, and is expected to reach USD 10,26.9 Mn by 2025, expanding at a CAGR of 3.2% from 2017 to 2025.
Browse Full Report Visit - http://www.acutemarketreports.com/report/malignant-ascites-treatment-market
Market Insights
Malignant ascites indicates presence of malignant cells in the peritoneal cavity. The most common malignancies linked with development of malignant ascites are cancers of ovary, colon/rectum, breast, lung, liver, lungs and lymphoma. The survival rate of such patients is poor; however appropriate treatment modality can improve the quality of life. Approximately half of the patients with malignant ascites have peritoneal carcinomatosis with additional 30% patients with liver metastases leading to portal hypertension. Traditional therapies for malignant ascites include paracentesis, shunting, drugs such as spironolactone, catumaxomab, and chemotherapy. With the advent of monoclonal antibody for treatment of malignancies, the catumaxomab is being increasingly preferred in palliative care of malignant ascites. Among the available treatment options, paracentesis is the most preferred option with higher success rates. However associated health risks with repeated procedures, alternatives and adjuncts such as chemotherapy and catumaxomab are being highly preferred by physicians in developed markets
North America was observed as the leading geographical region in malignant ascites treatment market driven by key factors such as aging population coupled with cancer complications, rising prevalence of several cancers, strong treatment pipeline, and rising awareness in medical practitioners associated with complexities related to ascites. During the forecast period 2016 – 2024, Japan was observed as the largest market in Asia-Pacific due to peaking geriatric population, increasing prevalence of cancers, and high public awareness related with early diagnosis coupled with several government initiatives. The other countries such as India, South Korea, Malayasia, Indonesia, Australia and Thailand are expected to observed significant growth in the near future due to developing healthcare infrastructure, availability of highly skilled oncologists and upcoming research and development facilities.
North America was observed as the leading geographical region in malignant ascites treatment market driven by key factors such as aging population coupled with cancer complications, rising prevalence of several cancers, strong treatment pipeline, and rising awareness in medical practitioners associated with complexities related to ascites. During the forecast period 2016 – 2024, Japan was observed as the largest market in Asia-Pacific due to peaking geriatric population, increasing prevalence of cancers, and high public awareness related with early diagnosis coupled with several government initiatives. The other countries such as India, South Korea, Malayasia, Indonesia, Australia and Thailand are expected to observed significant growth in the near future due to developing healthcare infrastructure, availability of highly skilled oncologists and upcoming research and development facilities.
Market Competition Assessment:
The malignant ascites market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are AstraZeneca plc, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems, Inc., Neovii Pharmaceuticals AG, Pfizer, Inc., Novartis AG, and GI Supply
Key Market Movements:
• High prevalence of cancers leading to ascites especially ovarian cancer, breast cancer, gastrointestinal cancer and colorectal cancer
• Growing research in management of cancers and related ascites is increasing and the diagnosis of ascites is also expected to enhance over the period of time
• The key challenge faced in malignant ascites treatment market is limited prognosis and difficulties in treating ascites
• The major opportunity in malignant ascites treatment market is due to high unmet needs for treatment of malignant ascites and strong treatment pipeline
• Growing research in management of cancers and related ascites is increasing and the diagnosis of ascites is also expected to enhance over the period of time
• The key challenge faced in malignant ascites treatment market is limited prognosis and difficulties in treating ascites
• The major opportunity in malignant ascites treatment market is due to high unmet needs for treatment of malignant ascites and strong treatment pipeline
Browse All Reports of This Category - http://www.acutemarketreports.com/category/pharmaceutical-market
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Malingant Ascites Market Portraiture
2.1 Global Malingant Ascites Market Portraiture
Chapter 3 Malignant Ascites Market Analysis
3.1 Malingnant Ascites Disease Overview
3.2 Malingnant Ascites Disease Diagnosis & Treatment Analysis
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 High Prevalence of cancers leading to ascites
3.3.1.2 Growing research in management of cancers and related ascites
3.3.2 Challenges
3.3.2.1 Limited Prognosis and difficulties in treating ascites
3.3.3 Opportunities
3.3.3.1 Huge unmet needs for treatment of malignant ascites and strong treatment pipeline
3.4 Attractive Investment Proposition, 2015
3.5 Market Positioning of Key Players in Malignant Ascites Market
3.1 Malingnant Ascites Disease Overview
3.2 Malingnant Ascites Disease Diagnosis & Treatment Analysis
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 High Prevalence of cancers leading to ascites
3.3.1.2 Growing research in management of cancers and related ascites
3.3.2 Challenges
3.3.2.1 Limited Prognosis and difficulties in treating ascites
3.3.3 Opportunities
3.3.3.1 Huge unmet needs for treatment of malignant ascites and strong treatment pipeline
3.4 Attractive Investment Proposition, 2015
3.5 Market Positioning of Key Players in Malignant Ascites Market
Chapter 4 Global Malignant Ascites Market Analysis, by Key Treatment
4.1 Introduction
4.2 Therapeutic Treatment
4.2.1 Spironolactone & Furosemide
4.2.2 Catumaxomab
4.2.3 Chemotherapy
4.3 Surgical Treatment
4.3.1 Paracentesis
4.3.2 Transjugular Intrahepatic Portosystemic Shunt (TIPS)
4.1 Introduction
4.2 Therapeutic Treatment
4.2.1 Spironolactone & Furosemide
4.2.2 Catumaxomab
4.2.3 Chemotherapy
4.3 Surgical Treatment
4.3.1 Paracentesis
4.3.2 Transjugular Intrahepatic Portosystemic Shunt (TIPS)
To Get Complete Report @ http://www.acutemarketreports.com/report/malignant-ascites-treatment-market
Chapter 5 Global Malignant Ascites Treatment Market, By Type of Application
5.1 Overview
5.2 Ovarian Cancer
5.3 Breast Cancer
5.4 Gastrointestinal Cancer
5.5 Colorectal Cancer
5.6 Carcinoma of Unknown Primary
5.7 Other Cancers
5.1 Overview
5.2 Ovarian Cancer
5.3 Breast Cancer
5.4 Gastrointestinal Cancer
5.5 Colorectal Cancer
5.6 Carcinoma of Unknown Primary
5.7 Other Cancers
Chapter 6 Global Malignant Ascites Treatment Market, By Geography
6.1 Preface
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 U.K.
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1 China
6.4.2 Japan
6.4.3 Rest of Asia-Pacific
6.5 Latin America
6.1 Preface
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 U.K.
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1 China
6.4.2 Japan
6.4.3 Rest of Asia-Pacific
6.5 Latin America
Latest Reports :
http://www.acutemarketreports.com/report/3d-bioprinters-market
http://www.acutemarketreports.com/report/3d-bioprinters-market
Our Blog :- http://www.newzmarket.com/
About - Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us :
Name : Chris Paul
ACUTE MARKET REPORTS
Designation : Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
No comments:
Post a Comment